|
Novel C3aR
agonists and antagonists for inhibiting pro-inflammatory activities of the human
complement system targeting C3aR
Princeton Docket # 12-2813
Novel agonists to C3aR have been designed using a de novo design
framework. The best predicted peptides were experimentally validated using a rat
basophilic leukemia cell degranulation assay and...
Published: 3/15/2018
|
Inventor(s): Christodoulos Floudas (deceased) See Fotini P. Baba, Meghan Bellows Peterson, Dimitrios Morikis, Peter Monk, Trent Woodruff
Keywords(s):
Category(s): Biotechnology/Pharmaceuticals
|
|
Princeton
University Invention # 10-2571
Using a novel computation framework,
researchers at Princeton University and the University of California, Riverside,
have identified potent antagonists of the C3a receptor (C3aR). Inhibition of
binding of C3a to C3aR is an excellent target for drug design against autoimmune
and inflammatory diseases involving...
Published: 3/15/2018
|
Inventor(s): Christodoulos Floudas (deceased) See Fotini P. Baba, Ho ki Fung, Meghan Bellows Peterson, Dimitrios Morikis, Chris Kieslich, Li Zhang
Keywords(s):
Category(s): Biotechnology/Pharmaceuticals
|
|
Princeton
University Invention # 09-2488
The
present invention relates to a series of novel analogues to compstatin. Based on
experimental SPR (Surface Plasmon Resonance) and IC50 binding data these new
analogues show greater binding affinity compared to native compstatin and are
therefore potentially more potent drug candidates for diseases related...
Published: 3/15/2018
|
Inventor(s): Christodoulos Floudas (deceased) See Fotini P. Baba, Meghan Bellows Peterson, Dimitrios Morikis
Keywords(s): small molecule, therapeutic
Category(s): Biotechnology/Pharmaceuticals
|